FindTrial
Sign In

Afimoxifene

DRUG4 trials

Sponsors

Northwestern University, M.D. Anderson Cancer Center

Conditions

Cancer SurvivorDuctal Breast Carcinoma In SituDuctal Breast Carcinoma in SituEstrogen Receptor PositiveEstrogen Receptor-positive Breast CancerInvasive Breast CarcinomaMammographically Dense Breast

Phase 2

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
CompletedNCT00952731
Northwestern UniversityDuctal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Start: 2009-12-31Updated: 2015-07-21
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
CompletedNCT02993159
Northwestern UniversityDuctal Breast Carcinoma In Situ, Estrogen Receptor Positive
Start: 2017-05-31End: 2022-01-24Updated: 2024-12-18
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
CompletedNCT03063619
M.D. Anderson Cancer CenterMammographically Dense Breast
Start: 2018-01-30End: 2021-10-26Updated: 2024-02-22
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
Active, not recruitingNCT04009044
Northwestern UniversityCancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Start: 2020-02-17End: 2026-06-25Target: 156Updated: 2025-10-09

Related Papers

Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ
JAMA Surgery2023-10-238 citations
A phase IIB pre-surgical trial of oral tamoxifen (TAM) versus transdermal 4-hydroxytamoxifen (4-OHT) in women with DCIS of the breast.
Journal of Clinical Oncology2018-05-201 citations